Squamous Cell Carcinoma of the Lung: Molecular Subtypes and Therapeutic Opportunities
Pablo Perez-Moreno, Elisabeth M. Brambilla, Roman Kurt Thomas et al. · Clinical Cancer Research · 2012
Lung cancer is the leading cause of cancer-related deaths worldwide. Next to adenocarcinoma, squamous cell carcinoma (SCC) of the lung is the most frequent histologic subtype in non-small cell lung cancer. Encouraging new treatments (i.e., bevacizumab, EGFR tyrosine kinase inhibitors, and ALK inhibitors) have afforded benefits to patients with adenocarcinoma, but unfortunately the same is not true for SCC. However, many genomic abnormalities are present in SCC, and there is growing evidence of their biologic significance. Thus, in the short term, the molecular characterization of patients with SCC in modern profiling platforms will probably be as important as deciphering the molecular genetics of adenocarcinoma. Patients with SCC of the lung harboring specific molecular defects that are actionable (e.g., fibroblast growth factor receptor 1 amplification, discoidin domain receptor 2 mutation, and phosphoinositide 3-kinase amplification) should be enrolled in prospective clinical trials targeting such molecular defects.
Cited by 348 works. doi:10.1158/1078-0432.ccr-11-2370
Authors
References
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- SEER Cancer Statistics Review, 1975-2003
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- Mutations of the BRAF gene in human cancer
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
- COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling